Accessible Search Form           Advanced Search

FY2012 Budget

DEPARTMENT OF HEALTH AND HUMAN SERVICES
NATIONAL INSTITUTES OF HEALTH
National Heart, Lung, and Blood Institute(NHLBI)





Organization chart

Org Chart and link to accessible version

For carrying out section 301 and title IV of the Public Health Services Act with respect to cardiovascular, lung, and blood diseases and blood products $3,147,992,000.


Amounts Avaliable for Obligation (1)

(Dollars in Thousands)


Source of Funding
FY 2010
Actual
FY 2011
CR
FY 2012
PB
Appropriation $3,096,916 $3,096,916 $3,147,992
Type 1 Diabetes 0 0 0
Rescission 0 0 0
Supplemental 0 0 0
Subtotal, adjusted appropriation
$3,096,916 $3,096,916
$3,147,992




Real transfer under Director's one-percent transfer authority (GEI) -$2,845 0 0
Real transfer under Secretary's one-percent transfer authority -$463 0 0
Comparative Transfers to NLM for NCBI and Public Access -$1,182 -$2,634 0
Comparative transfer under Director's one-percent transfer authority (GEI) $2,845 0 0
Comparative transfer under Secretary's one-percent transfer authority 0 0 0
       
Subtotal, adjusted budget authority $3,095,271 $3,094,282 $3,147,992
Unobligated balance, start of year 0 0 0
Unobligatied balance, end of year 0 0 0
       
Subtotal, adjusted budget authority $3,095,271 $3,094,282 $3,147,992
Unobligated balance lapsing -$107 0 0
       
Total obligation $3,095,164 $3,094,282 $3,147,992

(1)Excludes the following amounts for reimbursable activities carried out by this account:
FY 2010 - $50,029 FY 2011 - $25,000 FY 2012 - $25,000



Budget Mechanism-Total
(dollars in thousands)


MECHANISM
FY 2010
Actual
FY 2011
CR
FY 2012
PB
Change vs.
FY 2010
Research Grants: No. Amount No. Amount No. Amount No. Amount
Research Projects:
     Noncompeting 2,959 $1,554,173 2,948 $1,585,000 2,825 $1,598,748 (134) $44,575
        Administrative supplements (119) 7,500 (119) 7,700 (119) 7,000 0 (500)
     Competing:                
        Renewal 262 153,880 237 141,279 251 151,095 (11) (2,785)
        New 640 313,928 579 288,222 613 308,247 (27) (5,681)
        Supplements 1 247 0 0 0 0 (1) (247)
           Subtotal, Competing 903 $468,055 816 $429,501 864 $459,342 (39) ($8,713)
           Subtotal, RPGs 3,862 $2,029,728 3,764 $2,022,201 3,689 $2,065,090 (173) $35,362
SBIR/STTR 165 $76,400 165 $71,000 165 $71,000 0 ($5,400)
Research Project Grants 4,027 $2,106,128 3,929 $2,093,201 3,854 $2,136,090 (173) $29,962
Research Centers:
     Specialized/comprehensive 39 $71,650 62 $59,920 53 $60,000 14 ($11,650)
     Clinical research 0 0 0 0 0 0 0 0
     Biotechnology 0 0 0 0 0 0 0 0
     Comparative medicine 0 855 0 455 0 455 0 (400)
     Research Centers in Minority Institutions 0 0 0 0 0 0 0 0
Research Centers 39 $72,505 62 $60,375 53 $60,455 14 ($12,050)
Other Research:





      Research careers 591 $81,701 591 $81,701 591 $82,518 0 $817
      Cancer education 0 0 0 0 0 0 0 0
      Cooperative clinical research 11 18,650 44 43,000 48 47,000 37 28,350
      Biomedical research support 0 0 0 0 0 0 0 0
      Minority biomedical research support 11 2,608 14 3,000 16 3,200 5 592
      Other 120 26,300 120 26,000 120 26,000 0 (300)
Other Research 733 $129,259 769 $153,701 775 $158,718 42 $29,459
Total Research Grants 4,799 $2,307,892 4,760 $2,307,277 4,682 $2,355,263 (117) $47,371
                     
Research Training FTTPs   FTTPs   FTTPs      
      Individual Awards 275 $11,283 271 $11,283 271 $11,734 (4) $451
      Institutional Awards 1,777 86,711 1,768 86,711 1,768 89,313 (9) 2,602
Total Research Training 2,052 $97,994 2,039 $97,994 2,039 $101,047 (13) $3,053
                     
Research & development contracts 170 $384,437 170 $376,921 170 $376,921 0 ($7,516)
      SBIR/STTR (15) ($2,538) (20) ($7,500) (20) ($8,000) (5) $5,462
      FTEs   FTEs   FTEs   FTEs  
Intramural Research 455 $185,304 456 $189,455 456 $190,900 1 $5,596
Research management and support 421 119,644 422 122,635 422 123,861 1 4,217
Construction   0   0   0   0
Buildings and Facilities   0   0   0   0
      Total, NHLBI 876 $3,095,271 878 $3,094,282 878 $3,147,992 2 $52,721
                 

1/ All items in italics are "non-adds". Items in parentheses are subtractions.

Major Changes in the Fiscal Year 2012 Budget Request

Major changes by budget mechanism and/or budget activity detail are briefly described below.  Note that there may be overlap between budget mechanism and activity detail and these highlights will not sum to the total change for the FY 2012 budget request for NHLBI, which is $52.721 million more than the FY 2010 Actual, for a total of $3,147.992 million.

Research Project Grants (RPGs; +$29.962 million; total $2,136.090 million):  NHLBI will continue to fund of competing RPGs—864 awards in FY 2012, a decrease of 39 from FY 2010.  About 2,825 noncompeting RPG awards, totaling $1,598.748 million will be made in FY 2012. 

Clinical Hematology Research Career Developmental Program (+$2.700 million; total $13.500 million):  Develop and maintain multidisciplinary career development programs in clinical hematology research to equip new academic researchers with the knowledge and skills to address complex problems in blood diseases, transfusion medicine and cellular therapies.

Pediatric Hydroxyurea Phase II Clinical Trial (Baby Hug) (+$1.904 million; total $11.045 million):  The objective of this RFP is to investigate the beneficial and adverse effects of early intervention with HU on very young children (ages 9-17 months) with sickle cell disease (SCD) through the first decade of life.  In addition, to evaluate organ function, growth and psychosocial development, and predictive value of biomarkers in this cohort of children.

Pulmonary Vascular-Right Ventricular Axis Research Program (+ $4.050 million; total $20.250 million):  The objective of this RFA is to identify novel cellular and molecular mechanisms of right ventricular (RV) function and dysfunction and define human RV disease in the setting of lung vascular pathology through multidisciplinary, collaborative research.
                       
Consortium of Lung Repair and Regeneration (+$4.900 million; total $26.300 million):  The objective of this RFA is to encourage multidisciplinary, innovative, and collaborative research to identify molecular and cellular mechanisms of lung repair and regeneration, and support development of pioneering tools, reagents, and model systems to enhance such investigations.

Cardiovascular Cell Therapy Research Network (CCTRN) (+$9.000 million; total $63.000 million):  This initiative was originally released in FY 2007.  The renewal proposes to extend the CCTRN to a second project period for an additional 7 years to continue to accelerate the field of cell-based therapies for cardiovascular diseases. 

Basic Research in Calcific Aortic Valve Disease (+$4.000 million; total $20.000 million):  This initiative will stimulate studies on calcific aortic valve disease (CAVD), encourage development of new animal models and research techniques, and recruit investigators from related fields, such as mineralization and bone physiology, extracellular matrix physiology, cell signaling, immunology, and molecular imaging.

Summary of Changes

(Dollars in Thousands)

FY 2010 Actual $3,095,271
FY 2012 Estimate 3,147,992
Net change $52,721


2012 Estimate Change from
FY 2010

CHANGES

FTEs
Budget
Authority

FTEs
Budget
Authority
A. Built-in:
1. Intramural research:
     a. Annualization of January
         2010 pay increase

$72,019   $427
     b. January FY 2012 pay increase
72,019   0
     c. One less day of pay (n/a for 2011)
72,019   (279)
     d. Payment for centrally furnished
         services

28,810   285
     e. Increased cost of laboratory supplies,
         materials, and other expenses       

90,071   883
Subtotal
    $1,316





2. Research management and support:
     a. Annualization of January 2010
         pay increase

$62,236   $368
     b. January FY 2012 pay increase
62,236   $368
     c. One less day of pay (n/a for 2011)
62,236   (241)
     d. Payment for centrally furnished services
20,015   198
     e. Increased cost of laboratory supplies,
         materials, and other expenses

41,610   400
Subtotal
    $725


     
Subtotal, Built-in
    $2,041

2012 Estimate Change from FY 2010
CHANGES No. Amount No. Amount
B. Program:
1. Research project grants:
     a. Noncompeting 2,825 $1,605,748 (134) $44,075
     b. Competing 864 459,342 (39) (8,713)
     c. SBIR/STTR 165 71,000 0 (5,400)
Total 3,854 $2,136,090 (173) $29,962
       
2. Research centers 53 $60,455 14 ($12,050)
3. Other research 775 158,718 42 29,459
4. Research training 2,039 101,047 (13) 3,053
5. Research and development contracts 170 376,921 0 (7,516)
Subtotal, extramural   $697,141   $42,908

FTEs   FTEs  
6. Intramural research 456 $190,900 1 $4,280
7. Research management and support 422 123,861 1 3,492
8. Construction   0   0
9. Buildings and Facilities   0   0
Subtotal, program 878 $3,147,992 2 $50,680

       
Total changes   $3,147,992   $52,721


Fiscal Year 2011 Budget Graphs

History of budget Authority and FTEs

Graph: Funding by FY and link to data tables for this and 3 graphs immediately following: FTEs by FY, Budget Mechanism breakout, and percent change from 08, by mechanism Graph: FTEs by FY and link to data table

Distribution by Mechanism

Graph: distribution by mechanism and link to data table

Change by Selected Mechanism

Graph: change by selected mechanism and link to data table


Budget Authority by Activity

(dollars in thousands)


FY 2010
Actual
FY 2011
CR
FY 2012
PB
Change vs.
FY 2010
Extramural Research FTEs Amount FTEs Amount FTEs Amount FTEs Amount
Detail:






Heart and Vascular Diseases   $1,771,213   $1,766,220   $1,798,621   $27,408
Lung Diseases   $629,938   $627,998   $639,519   $9,581
Blood Diseases and Resources   $389,172   $387,974   $395,091   $5,919

               
Subtotal, Extramural   $2,790,323   $2,782,192   $2,833,231   $42,908

               
Intramural research 455 $185,304 456 $189,455 456 $190,900 1 $1,445

               
Res. management & support 421 $119,644 422 $122,635 422 $123,861 1 $1,226

               
TOTAL 876 $3,095,271 878 $3,094,282 878 $3,147,992 2 $45,579

1 Includes FTEs which are reimbursed from the NIH Roadmap for Medical Research
2 Includes Real Transfers and Comparable Adjustments as detailed in the "Amounts Available for Obligation" table.

Authorizing Legislation graphic and link to description

Appropriations History

Fiscal
Year
Budget Estimate
to Congress
House
Allowance
Senate
Allowance

Appropriation





2003 $2,778,728,000 $2,791,411,000 $2,820,011,000 $2,812,011,000
Rescission


($18,278,000)





2004 $2,867,995,000 $2,867,995,00 $2,897,595,000 $2,897,145,000
Rescission


($18,454,000)





2005 $2,963,953,000 $2,963,953,000 $2,985,900,000 $2,965,453,000
Rescission


($24,252,000)





2006 2,951,270,000 2,951,270,000 3,023,381,000 2,951,270,000
Rescission



(29,513,000)





2007 2,918,808,000 2,901,012,000 2,924,299,000 2,918,808,000
Rescission



0





2008 2,894,341,000 2,965,775,000 2,992,197,000 2,974,900,000
Rescission


(51,972,000)
Supplemental



15,542,000





2009 2,924,942,000 3,025,500,000 3,006,344,000 3,015,689,000
Rescission


0





2010 3,050,356,000 3,123,403,000
3,066,827,000
3,096,916,000
Rescission



0
 


 
2011 3,187,516,000
$3,182,524,000

Rescission        
 



2012 $3,147,992,000


Justification of Budget Request

Authorizing Legislation: Section 301 and title IV of the Public Health Service Act, as amended.

 
FY2010 Actual FY 2011
Continuing
Resolution
FY 2012
Budget
Request
FY 2012 +/-
FY 2010
BA
$3,095,271,000 $3,094,282,000 $3,147,992,000 +52,721,000
FTE
876 878 878 +2

Program funds are allocated as follows: Competitive Grants/Cooperative Agreements; Contracts; Direct Federal/Intramural and Other.

DIRECTOR'S OVERVIEW

The NHLBI provides leadership for a research and education program to promote prevention and treatment of heart, blood vessel, lung, and blood diseases.  Guided by Shaping the Future of Research: A Strategic Plan, the NHLBI supports a robust, collaborative research enterprise, in partnership with private and public organizations, to address the scientific and educational needs of the nation. 
The NHLBI has long maintained a balanced portfolio of basic and clinical research activities and, in recent years, has increased its investment in translational approaches to bridge the gap between fundamental discoveries and clinical practice.  This emphasis is very much in line with broad based NIH efforts (e.g., Therapeutics for Rare and Neglected Diseases [TRND] and Rapid Access to Interventional Development [RAID]) in translation.  Strategies being used by the NHLBI to further this important work include:

  • Clinical research networks—infrastructures to enable the rapid development and conduct of multiple clinical protocols for assessment of promising diagnostic and therapeutic strategies for selected disease areas within the mandate of the Institute.
  • Production Assistance for Cell Therapy (PACT)—provision of cell-manufacturing facilities and technical expertise essential for advancing cellular therapy research in the areas of regeneration of damaged/diseased tissues, organs, and biologic systems as treatments for serious diseases that do not have effective therapies.
  • Bench-to-Bassinet Program—a pediatric cardiovascular program consisting of three interacting entities:  the Cardiovascular Development Consortium, to investigate the transcriptional regulatory networks that govern cardiac development, using complementary animal models; the Pediatric Cardiac Genomics Consortium, to speed discovery of causative genes and evaluate the effects of genetic variation on short- and long-term outcomes in patients with congenital heart disease; and the Pediatric Heart Network, to conduct clinical trials.
  • Cardiac Translational Research Implementation Program (C-TRIP)—a two-stage program to accelerate the translation of promising therapeutic interventions (derived from fundamental research discoveries) for the treatment and prevention of heart failure or arrhythmias.  Twelve planning and development awards were made in FY 2010, and several clinical trials of safety and efficacy that result from this initial effort will be awarded in FY 2012.
  • Grand Opportunities Translational Research Implementation Program (GO TRIP)—a program modeled on the C-TRIP, but applicable to all diseases and conditions within the mandate of the NHLBI.  GO TRIP’s initial stage was funded via the American Recovery and Reinvestment Act (ARRA), and the Institute is committed to supporting successful projects that result from this investment.
  • Phase II Clinical Trials of Novel Treatments for Lung Diseases—support for proof-of-concept testing of interventions that have the potential to revolutionize clinical management of a lung disease or sleep disorder.
  • Science Moving TowArds Research Translation and Therapy (SMARTT)—provision of resources for preclinical- and clinical-grade production and testing of new molecular entities for the treatment of heart, lung, and blood diseases. 
  • Centers for Advanced Diagnostics and Experimental Therapeutics in Lung Diseases—development of diagnostics and/or therapeutics for lung diseases and sleep-disordered breathing that will emphasize structured interactions, collaborations, and data-sharing among participants.
  • NHLBI Clinical Trial Pilot Studies—a program to enable more competitive investigator-initiated clinical trial grant applications and more robust and successful clinical trials that evaluate interventions for the treatment or prevention of heart, lung, blood, or sleep disorders.
  • Planning Grants for Pivotal Clinical Trials in Hemoglobinopathies—support of activities necessary to assess feasibility and to develop pilot studies required for the design of full-scale clinical trials.

 

The Institute is also deeply committed to ensuring that the findings of its research programs are rapidly incorporated into public health programs and into the everyday practice of therapeutic and preventive medicine.  Public outreach in asthma, women’s heart health, and COPD continues to yield positive results.  The NHLBI is developing updated evidence-based guidelines for hypertension, blood cholesterol, and obesity and preparing integrated guidelines to aid practitioners in managing patients with multiple conditions.  New guidelines are being developed for pediatric cardiovascular disease prevention and for sickle cell disease and will be widely disseminated.

Over the past several years the Institute has placed strong emphasis on use of cutting-edge approaches to explore genetic influences on heart, lung, and blood diseases.  All NHLBI-supported genotyping efforts have been made available for further research by qualified investigators, thus maximizing the scientific return possible from these valuable data.  Beginning with genotyping the participants of the Framingham Heart Study, the NHLBI has made a substantial investment in supporting genotyping of its well-phenotyped cohorts.  For example, the SNP Typing for Association with Multiple Phenotypes from Existing Epidemiological Data (STAMPEED) program was developed to support studies to identify genetic variants related to heart, lung, and blood disorders and their risk factors using genome-wide association studies.  The NHLBI initiated the Candidate-gene Association Resource (CARe) to create a shared genotype/phenotype resource comprising nine NHLBI-funded cohort studies; it also is required to be made available for research by other investigators.  More recently, six ARRA-funded signature projects were supported for exome sequencing of additional well-phenotyped NHLBI population cohorts.  These one-time investments in a shared genetic association database have already yielded significant findings that are exploited to identify disease mechanisms and therapeutic targets; the ongoing availability of these data is expected to yield unprecedented scientific and medical advances as investigators take advantage of this rich source of information. 

The NHLBI also intends to continue its interest in supporting efforts to develop the therapeutic and curative potential of stem cells.  Four projects were funded via ARRA to address important gaps in knowledge of induced pluripotent stem cells, including the extent to which they are equivalent to embryonic stem cells and whether they can be used for clinical research in the future.  Because many critical questions remain about the utility in regenerative medicine of induced pluripotent stem cells or even embryonic stem cells, NHLBI fully expects to continue its investment in this critically important area.

Overall Budget Policy:  The FY 2012 request for NHLBI is $3,147.992 million, an increase of $52.721 million or +1.7 percent over the FY 2010 actual.  NHLBI will continue to support early stage investigators and to maintain a balance between solicitations issued to the extramural community and funding made available to support investigator-initiated projects.  In FY 2012, NHLBI is providing a 1 percent inflationary increase for non-competing and 2.4 percent for competing grants.  The Institute also seeks priority to support highly meritorious new research projects and ongoing initiatives.  In addition, NHLBI will provide an increase of four percent for stipends levels under the Ruth L. Kirschstein National Research Service Award training program to continue efforts to attain the stipend levels recommended by the National Academy of Sciences.  This will build on the two percent increase in stipend levels for FY 2011.  Stipend levels were largely flat for several years, and the requested increase will help to sustain the development of a highly qualified biomedical research workforce.  Intramural Research and Research Management and Support will receive an increase to help cover support of ongoing research and modest expansion of new programs.  Funds are included in R&D contracts to reflect NHLBI’s share of NIH-wide funding required to support several trans-NIH initiatives, such as the Therapies for Rare and Neglected Diseases program, the Basic Behavioral and Social Sciences Opportunity Network (OppNet), and support for a new synchrotron at the Brookhaven National Laboratory.  For example, each IC that will benefit from the new synchrotron will provide funding to total NIH’s commitment to support this new technology--$10 million.

 

Program Descriptions and Accomplishments

Heart and Vascular Diseases

This program supports research on the causes, diagnosis, treatment, and prevention of heart and vascular diseases.  Research areas include atherothrombosis, coronary artery disease, myocardial infarction and ischemia, heart failure, arrhythmia, sudden cardiac death, adult and pediatric congenital heart disease, cardiovascular complications of diabetes and obesity, and hypertension.  The program’s efforts encompass basic, translational, clinical, epidemiological, behavioral, nutritional, comparative-effectiveness, international, and health services research disciplines.  In FY 2010, NHLBI initiated collaborative research projects to develop an integrated understanding of cardiomyocyte mitochondria and its contributions to myocardial adaptations and heart disease progression, renewed support for the Resuscitation Outcomes Consortium, and established Cardiovascular Outcomes Research Centers.  In FY 2011, the Institute will fund a renewal of its Pediatric Heart Network and a follow-up study of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial.

Budget Policy:  The FY 2012 budget estimate for the Heart and Vascular Diseases program is $1,798.621 million, an increase of $27.408 million or 1.55% over the FY 2010 actual.  During FY 2012 NHLBI plans to continue support of genome-wide studies.  The program plans for FY 2012 include support for an initiative to conduct large scale, high density, high throughput 3rd generation genome-wide genotyping to characterize genetic variation among member of the Hispanic Community Health Study/Study of Latinos.  This initiative will create the infrastructure necessary to identify disease-related genes, explore context-dependent effects, and leverage the phenotypic resources of the largest existing Hispanic study cohort.

Portrait of a Program: Cardiac Translational Research Implementation Program (C-TRIP)

FY 2010 Level:  $ 8.665 million
FY 2012 Level:  $ 13.635million
Change:              $ 4.970 million

The C-TRIP is a two-phase initiative to accelerate translation of promising new therapeutic interventions derived from fundamental research discoveries for the treatment and prevention of heart failure or arrhythmias.  It supports the planning and execution of well-designed clinical trials to demonstrate safety and efficacy.  In the initial phase begun during FY 2010, twelve exploratory planning grants were awarded for two-year project periods to enable study development and trial planning.  During FY 2012, the awardees will be eligible to compete for five years of funding to perform human-subject trials of new therapeutic interventions with a primary goal of providing evidence of efficacy and safety.  It is expected that up to four awards will be made for interventional trials that show promise of completing all milestones established during the initial phase and evidence of readiness for implementation upon award. 

Lung Diseases

This program supports research on the causes, diagnosis, treatment, and prevention of lung diseases and sleep disorders.  Research areas include asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, critical care and acute lung injury, developmental biology and pediatric pulmonary diseases, immunology and fibrosis, lung cell and vascular biology, and pulmonary complications of AIDS and tuberculosis.  The National Center on Sleep Disorders Research is administered within the Lung Diseases program.  In FY 2010, the NHLBI funded the Prematurity and Respiratory Outcomes Program (PROP) to investigate molecular mechanisms that contribute to respiratory disease risk of the premature newborn and supported planning grants for clinical trials of lung transplantation.  In FY 2011, the NHLBI will initiate research to explore common pathogenetic mechanisms of lung cancer and COPD and renew the Severe Asthma Research Program.

Budget Policy:  The FY 2012 budget estimate for the Lung Diseases program is $639.519 million, an increase of $9.581 million or 1.52% over the FY 2010 actual.  In FY 2012 the program will continue to support the initiative to identify the fundamental etiologic, pathologic, and genetic commonalities between lung cancer and chronic obstructive pulmonary disease in order to characterize the determinants of individual susceptibility and the shared biochemical and immunological pathways involved in the origin and progression of the two diseases.   In FY 2012 the program plans to support a training initiative to increase the pool of medical students interested in an academic career in pediatric, sleep, or hematology/transfusion medicine.

Portrait of a Program: New Directions in Chronic Obstructive Pulmonary Disease (COPD)
FY 2010 Level:  $ 0
FY 2012 Level:  $ 4.400 million
Change:              $ 4.400 million 

The NHLBI COPD program seeks to elucidate the pathways by which the disease develops and progresses and to develop effective approaches for COPD management and prevention.  Investigators are exploring mechanisms of injury and repair in the lung and environmental and genetic determinants of COPD.  Applied studies are developing new methods of lung imaging and using them to characterize various subtypes of COPD and are measuring disease progression and outcomes.  The Learn More, Breathe Better campaign seeks to increase awareness that COPD is a serious, but treatable, lung disease and to encourage people at risk to have their breathing tested and talk to their doctors about treatment options.  During FY 2011, the NHLBI initiated a new program that brings together researchers from the pulmonary and cancer communities to investigate the common pathogenetic mechanisms of lung cancer and COPD.  By studying the genotypic and phenotypic characteristics of individuals with susceptibility to both diseases and the shared biochemical and immunological pathways involved, it is hoped that scientists will understand the fundamental processes that regulate the origin and progression of both diseases.  FY 2011 marks the final year of support for NHLBI Specialized Centers of Clinically Oriented Research in COPD.  In FY 2012 the NHLBI will fund the design and testing of a strategy for finding cases of moderate-to-severe COPD, with the ultimate goal of prompt and effective application of proven treatments to reduce morbidity and mortality.  A second initiative will support identification of early molecular abnormalities associated with alpha-1 antitrypsin deficiency in affected persons with or without clinical lung disease.  The Institute also plans to establish the Lung Repair and Regeneration Consortium to develop new research tools, reagents, and models to elucidate the lung’s capacity for regeneration.

 

 

Blood Diseases and Resources

This program supports research on the causes, prevention, and treatment of nonmalignant blood diseases, including anemias, sickle cell disease, and thalassemia; premalignant processes such as myelodysplasia and myeloproliferative disorders; abnormalities of hemostasis and thrombosis such as hemophilia; and immune dysfunction.  Another program responsibility is to support research and research training on the use, safety, efficacy, and availability of blood and blood components for transfusion and cellular therapeutics.  In FY 2010, NHLBI continued support for the landmark Clarification of Optimal Anticoagulation through Genetics (COAG) clinical trial of genotype-guided dosing of warfarin therapy.  In FY 2011, NHLBI will renew the Blood and Marrow Transplant Clinical Trials Network and fund new planning grants for pivotal clinical trials in hemoglobinopathies.

Budget Policy:  The FY 2012 budget estimate for the Blood Diseases and Resources program is $395.091 million, an increase of $5.919 million or 1.52% over the FY 2010 actual. The program plans for FY 2012 include continued support to accelerate research on the management of hematopoietic stem cell transplantation, standardize and compare the effectiveness and toxicities of existing treatments, and evaluate new therapies.  Another planned initiative will provide investigators with the resources (i.e., funding, biospecimens and associated data), to conduct exploratory research in heart, lung, and blood diseases, and blood resources.  This program will provide investigators with an opportunity to obtain preliminary data using human biospecimens in a timely and cost effective manner.  These data can be used in future grant applications to advance the mission of NHLBI.

Portrait of a Program: Translational Research Centers in Thrombotic and Hemostatic Disorders
(TRC-THD)
FY 2010 Level: $ 0 million
FY 2012 Level: $ 14.000 million
Change:             $ 14.000 million

The TRC-THD program is designed to accelerate the translation of basic research discoveries into improved approaches for prevention, diagnosis, and treatment of thrombotic and hemostatic disorders.  Early-stage translation research will integrate applied and basic science to move scientific discoveries toward clinical application.  Collaboration between the new centers and NIH Clinical and Translational Science Award programs or institutional programs with similar capabilities is expected to leverage resources and facilitate navigation of regulatory obstacles.  The NHLBI anticipates funding five centers, each of which would address a different clinical question.  Expected outcomes of this endeavor are the identification of predictive markers of risk, development of improved diagnostic tools, and discovery of new therapeutic agents.  This new program supplants the NHLBI Specialized Centers of Clinically Oriented Research (SCCOR) in Hemostatic and Thrombotic Diseases program, which—although highly productive—did not emphasize early-stage translational research and ended in FY 2011.

 

 

Intramural Research

The NHLBI Intramural Research Program (IRP) conducts laboratory and clinical research in heart, vascular, lung, blood, and kidney diseases and develops technology related to cardiovascular and pulmonary diseases.  These studies extend from the basic structure and interaction of proteins and motility/energetics of cells to the clinical diagnosis and treatment of a wide range of diseases.  The program comprises six centers (Biochemistry and Biophysics, Cell Biology and Physiology, Genetics and Developmental Biology, Immunology, Molecular Medicine and Systems Biology) and two branches (Hematology, Cardiovascular and Pulmonary).  In FY 2010, the NHLBI IRP continued its contributions to two trans-NIH programs—the Center for Human Immunology and the Imaging Probe Development Center—which are administered and staffed by the NHBLI for the entire NIH campus.  The IRP conducted the first-ever Earl Stadtman Tenure Track search at the NIH level to recruit the next generation of scientists.  In fiscal year 2011, the program on Pediatric Imaging using MRI, in collaboration with the Children’s National Medical Center, will start seeing pediatric cases.  Its goals are to minimize ionizing radiation exposure, apply real-time MRI approaches to simple diagnostic procedures that avoid general anesthetics, and provide visual guides for minimally invasive surgery.  The program will complement a large effort in cardiovascular imaging, both on campus and at Suburban Hospital that seeks to improve diagnosis and treatment of heart disease.  The IRP is recruiting a new director for the Systems Biology Center who will be expected to develop a dynamic, highly productive program that can integrate with similar efforts across the NIH and provide national and international leadership in selected areas.

Budget Policy:  The FY 2012 budget estimate for the Intramural Research program is $190.900 million, an increase of $5.596 million or 3.0% from the FY 2010 actual. Resources will support ongoing research and modest expansion of new programs.

 

Research Management and Support

This activity provides administrative management and scientific direction in the review, award, and monitoring of research grants, training awards, and research and development contracts and in the overall planning, coordination, and evaluation of the Institute’s programs.  The Division for the Application of Research Discoveries (DARD) continued its We Can! ® Program, which addresses overweight and obesity in children 8 through 13 years of age.  In FY 2010, We Can! ® and its partners held nine instructional regional trainings for over 700 participants, who will bring the program into their communities across the country.  In FY 2011, the DARD plans to release and begin to implement pediatric integrated cardiovascular risk reduction guidelines, complete and release sickle cell disease guidelines, and release clinical guidelines on hypertension, cholesterol, and obesity.  The Office of Communications (OC) provides comprehensive, integrated, and technology-supported communications abilities to help the NHLBI achieve its mission.  In FY 2010, the OC focused NHLBI efforts to celebrate a century of progress in sickle cell disease research and care through briefings, public health information, and coalition-building activities to prepare partners and the sickle cell community for the abovementioned release of sickle cell disease guidelines.  In FY 2011, the OC will begin implementing the Institute’s new Web strategies, integrating a new content management system and full information architecture redesign to improve public access to research and health information.

Budget Policy:  The FY 2012 budget estimate for Research Management and Support is $123.861 million, an increase of $4.217 million or 3.5% over the FY 2010 actual.

 

Budget Authority by Object

(Dollars in Thousands)

  FY 2010
Actual
FY 2012
PB
Increase or
Decrease
Percent Change
Total compensable workyears:

       
        Full-time employment 876 878 2 0.2%
        Full-time equivalent of overtime and holiday hours 1 1 0 0.0%

     
        Average ES salary $0 $0 $0 0.0%
        Average GM/GS grade 12.4 12.4 0.0 0.0%

     
        Average GM/GS salary $101,662 $101,662 $0 0.0%
        Average salary, grade established by act of July 1, 1944 (42 U.S.C. 207) $98,431 $98,431 $0 0.0%
        Average salary of ungraded positions 129,823 129,823 0 0.0%


OBJECT CLASSES

FY 2010
Actual
FY 2012
Estimate
Increase or
Decrease
Percent
Change

Personnel Compensation:



 
11.1 Full-time permanent $60,342 $61,638 $1,296 2.1
11.3 Other than full-time permanent 32,096 32,764 668 2.1
11.5 Other personnel compensation 3,808 3,890 82 2.2
11.7 Military personnel 783 824 41 5.2
11.8 Special personnel services payments 8,187 8,356 169 2.1
Total, Personnel Compensation 105,216 107,472 2,256 2.1
12.0 Personnel benefits 25,706 26,250 544 2.1
12.2 Military personnel benefits 535 546 11 2.1
13.0 Benefits for former personnel 0 0 0 0.0
Subtotal, Pay Costs 131,457 134,268 2,811 2.1
21.0 Travel and transportation of persons 3,411 3,663 252 7.4
22.0 Transportation of things 276 296 20 7.2
23.1 Rental payments to GSA 2 2 0 0.0
23.2 Rental payments to others 3 3 0 0.0
23.3 Communications, utilities and
miscellaneous charges
1,058 1,137 79 7.5
24.0 Printing and reproduction 261 281 20 7.7
25.1 Consulting services 2,139 2,265 126 5.9
25.2 Other services 33,409 34,995 1,586 4.7
25.3 Purchase of goods and services from
government accounts
220,357 220,603 246 0.1
25.4 Operation and maintenance of facilities 2,086 2,239 153 7.3
25.5 Research and development contracts 265,621 259,976 (5,645) -2.1
25.6 Medical care 1,880 2,018 138 7.3
25.7 Operation and maintenance of equipment 4,239 4,551 312 7.4
25.8 Subsistence and support of persons 0 0 0 0.0
25.0 Subtotal, Other Contractual Services 529,731 526,647 (3,084) -0.6
26.0 Supplies and materials 14,411 15,468 1,057 7.3
31.0 Equipment 9,238 9,917 679 7.4
32.0 Land and structures 0 0 0 0.0
33.0 Investments and loans 0 0 0 0.0
41.0 Grants, subsidies and contributions 2,405,423 2,456,310 50,887 2.1
42.0 Insurance claims and indemnities 0 0 0 0.0
43.0 Interest and dividends 0 0 0 0.0
44.0 Refunds 0 0 0 0.0

Subtotal, Non-Pay Costs
2,963,814 3,013,724 49,910 1.7
Total Budget Authority by Object 3,095,271 3,147,992 52,721 1.7

Includes FTEs which are reimbursed from the NIH Common Fund for Medical Research

Salaries and Expenses

(Dollars in Thousands)

OBJECT CLASSES

FY 2010
Actual
FY 2012
PB
Increase or
Decrease
Percent
Change

Personnel Compensation:



 
      Full-time permanent (11.1) $60,342 $61,638 $1,296 2.1
      Other than full-time permanent (11.3) 32,096 32,764 668 2.1
      Other personnel compensation (11.5) 3,808 3,890 82 2.2
      Military personnel (11.7) 783 824 41 5.2
      Special personnel services payments (11.8) 8,187 8,356 169 2.1
Total Personnel Compensation (11.9) 105,216 107,472 2,256 2.1
Civilian personnel benefits (12.1) 25,706 26,250 544 2.1
Military personnel benefits (12.2) 535 546 11 2.1
Benefits to former personnel (13.0) 0 0 0 0.0
Subtotal, Pay Costs 131,457 134,268 2,811 2.1
Travel (21.0) 3,411 3,663 252 7.4
Transportation of things (22.0) 276 296 20 7.2
Rental payments to others (23.2) 3 3 0 0.0
Communications, utilities and
miscellaneous charges (23.3)
1,058 1,137 79 7.5
Printing and reproduction (24.0) 261 281 20 7.7
Other Contractual Services:        
      Advisory and assistance services (25.1) 2,139 2,265 126 5.9
      Other services (25.2) 33,409 34,995 1,586 4.7
      Purchases from government accounts (25.3) 197,580 198,271 691 0.3
      Operation and maintenance of facilities (25.4) 2,086 2,239 153 7.3
      Operation and maintenance of equipment (25.7) 4,239 4,551 312 7.4
      Subsistence and support of persons (25.8) 0 0 0 0.0
Subtotal Other Contractual Services 239,453 242,321 2,868 1.2
Supplies and materials (26.0) 14,286 15,333 1,047 7.3
Subtotal, Non-Pay Costs 258,748 263,034 4,286 1.7

       
Total, Administrative Costs 390,205 397,302 7,097 1.8



Details of Full-Time Equivalent Employment (FTEs)


OFFICE/DIVISION
FY 2010
Actual
FY 2011
CR
FY 2012
PB
  Civilian Military Total Civilian Military Total Civilian Military Total
Office of the Director 99 1 100 100 1 101 100 1 101
Division of Blood Diseases and Resources 25   25 25 0 25 25 0 25
Division of Lung Diseases 26   26 26 0 26 26 0 26
Division for the Application of Research Discoveries 24   24 24 0 24 24 0 24
Division of Intramural Research 448 7 455 450 6 456 450 6 456
Division of Cardiovascular Sciences 124 1 125 124 1 125 124 1 125
Division of Extramural Research Activities 121 0 121 121 0 121 121 0 121

                 
Total 867 9 876 870 8 878 870 8 878

Includes FTEs which are reimbursed from the NIH Common Fund for Medical Research.
FTEs supported by funds from Cooperative Research
and Development Agreements

0 0  

 

FISCAL YEAR
Average GM/GS Grade
2008
12.2
2009
12.4
2010
12.4
2011
12.4
2012
12.4

Detail of Positions


GRADE
FY 2010
Actual
FY 2011
CR
FY 2012
PB
Total, ES Positions 0 0 0
Total, ES Salary 0 0 0
GM/GS-15 96 96 96
GM/GS-14 136 138 138
GM/GS-13 161 161 161
GS-12 91 91 91
GS-11 46 46 46
GS-10 1 1 1
GS-9 53 53 53
GS-8 25 25 25
GS-7 12 12 12
GS-6 6 6 6
GS-5 6 6 6
GS-4 2 2 2
GS-3 1 1 1
GS-2 0 0 0
GS-1 0 0 0
Subtotal 636 638 638




Grades established by Act of
July 1, 1944 (42 U.S.C. 207):
Assistant Surgeon General 1 1 1
Director Grade 5 4 4
Senior Grade 1 1 1
Full Grade 2 2 2
Senior Assistant Grade 0 0 0
Assistant Grade 0 0 0
Subtotal 9 8 8
Ungraded 296 297 297

     
Total permanent positions 642 642 642

     
Total positions, end of year 941 943 943

     
Total full-time equivalent (FTE) employment, end of year 876 878 878
       
Average ES salary 0 0 0
Average GM/GS grade 12.4 12.4 12.4
Average GM/GS salary 101,662 101,662 101,662

New Positions Requested

  FY 2012
  Grade Number Annual
Salary
Health Science Administrator GS-14 1 $120,907
Clinical Trials Specialist GS-14 1 $120,907
Total Requested   2 $241,814

Last Updated February 2011

Twitter iconTwitterimage of external icon Facebook iconFacebookimage of external icon YouTube iconYouTubeimage of external icon Google+ iconGoogle+image of external icon